Ex­clu­sive: Gene edit­ing start­up Seam­less hires ex-Ho­mol­o­gy leader, dou­bles seed round

A small Ger­man biotech at­tempt­ing to crack in­to the gene edit­ing field with an evolved ap­proach to a decades-old re­search in­ter­est has nabbed for­mer Ho­mol­o­gy Med­i­cines ex­ec­u­tive Al­bert Sey­mour as CEO.

Seam­less Ther­a­peu­tics, which emerged last year with about $12.5 mil­lion, is ex­pand­ing in­to the Boston area and tack­ing on an­oth­er $12.5 mil­lion led by For­bion and Welling­ton Part­ners, the biotech told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER